Drug intelligence / Profile preview

TA-100

Development stage: Preclinical
Lead developer: Pfizer
Modality: Recombinant Proteins and Enzymes

Overview

**TA-100** is a protein-based decoy receptor drug targeting **FGFR3** (fibroblast growth factor receptor 3), initially developed by **Atos SE**. It functions by sequestering FGFR3 ligands to inhibit pathological FGFR3 signaling, which is implicated in certain congenital skeletal disorders such as achondroplasia. Currently in **preclinical** development, it addresses needs in **congenital disorders**, **endocrinology and metabolic diseases**, and **skin and musculoskeletal diseases**.

Other names: FGFR3 DecoyFGFR-3 DecoyFGFR 3 Decoy

Targets

FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on TA-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TA-100.

Explore the full profile